183 related articles for article (PubMed ID: 33015850)
1. The ABCG2/BCRP transporter and its variants - from structure to pathology.
Sarkadi B; Homolya L; Hegedűs T
FEBS Lett; 2020 Dec; 594(23):4012-4034. PubMed ID: 33015850
[TBL] [Abstract][Full Text] [Related]
2. Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism.
Mózner O; Bartos Z; Zámbó B; Homolya L; Hegedűs T; Sarkadi B
Cells; 2019 Oct; 8(10):. PubMed ID: 31597297
[TBL] [Abstract][Full Text] [Related]
3. Single-nucleotide polymorphisms in a short basic motif in the ABC transporter ABCG2 disable its trafficking out of endoplasmic reticulum and reduce cell resistance to anticancer drugs.
Zhang W; Yang Y; Dong Z; Shi Z; Zhang JT
J Biol Chem; 2019 Dec; 294(52):20222-20232. PubMed ID: 31719146
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant mutations in the ABCG2 transporter uncovered by genetic analysis linked to erythrocyte membrane protein expression.
Zámbó B; Bartos Z; Mózner O; Szabó E; Várady G; Poór G; Pálinkás M; Andrikovics H; Hegedűs T; Homolya L; Sarkadi B
Sci Rep; 2018 May; 8(1):7487. PubMed ID: 29749379
[TBL] [Abstract][Full Text] [Related]
5. Medically Important Alterations in Transport Function and Trafficking of ABCG2.
Homolya L
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33801813
[TBL] [Abstract][Full Text] [Related]
6. The transport pathway in the ABCG2 protein and its regulation revealed by molecular dynamics simulations.
Nagy T; Tóth Á; Telbisz Á; Sarkadi B; Tordai H; Tordai A; Hegedűs T
Cell Mol Life Sci; 2021 Mar; 78(5):2329-2339. PubMed ID: 32979053
[TBL] [Abstract][Full Text] [Related]
7. ABCG2 as a therapeutic target candidate for gout.
Fujita K; Ichida K
Expert Opin Ther Targets; 2018 Feb; 22(2):123-129. PubMed ID: 29264928
[TBL] [Abstract][Full Text] [Related]
8. Functional Characterization of Clinically-Relevant Rare Variants in
Toyoda Y; Mančíková A; Krylov V; Morimoto K; Pavelcová K; Bohatá J; Pavelka K; Pavlíková M; Suzuki H; Matsuo H; Takada T; Stiburkova B
Cells; 2019 Apr; 8(4):. PubMed ID: 31003562
[TBL] [Abstract][Full Text] [Related]
9. The structure of the human ABC transporter ABCG2 reveals a novel mechanism for drug extrusion.
Khunweeraphong N; Stockner T; Kuchler K
Sci Rep; 2017 Oct; 7(1):13767. PubMed ID: 29061978
[TBL] [Abstract][Full Text] [Related]
10. Residues contributing to drug transport by ABCG2 are localised to multiple drug-binding pockets.
Cox MH; Kapoor P; Briggs DA; Kerr ID
Biochem J; 2018 May; 475(9):1553-1567. PubMed ID: 29661915
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
12. Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.
Toyoda Y; Pavelcová K; Bohatá J; Ješina P; Kubota Y; Suzuki H; Takada T; Stiburkova B
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669292
[TBL] [Abstract][Full Text] [Related]
13. Cryo-EM structures of a human ABCG2 mutant trapped in ATP-bound and substrate-bound states.
Manolaridis I; Jackson SM; Taylor NMI; Kowal J; Stahlberg H; Locher KP
Nature; 2018 Nov; 563(7731):426-430. PubMed ID: 30405239
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
15. Cellular expression and function of naturally occurring variants of the human ABCG2 multidrug transporter.
Zámbó B; Mózner O; Bartos Z; Török G; Várady G; Telbisz Á; Homolya L; Orbán TI; Sarkadi B
Cell Mol Life Sci; 2020 Jan; 77(2):365-378. PubMed ID: 31254042
[TBL] [Abstract][Full Text] [Related]
16. The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout-An Update.
Eckenstaler R; Benndorf RA
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206432
[TBL] [Abstract][Full Text] [Related]
17. Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.
Sjöstedt N; van den Heuvel JJMW; Koenderink JB; Kidron H
Pharm Res; 2017 Aug; 34(8):1626-1636. PubMed ID: 28281205
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia.
Pálinkás M; Szabó E; Kulin A; Mózner O; Rásonyi R; Juhász P; Nagy K; Várady G; Vörös D; Zámbó B; Sarkadi B; Poór G
Clin Exp Med; 2023 Aug; 23(4):1277-1284. PubMed ID: 35939175
[TBL] [Abstract][Full Text] [Related]
19. The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion.
Hoque KM; Dixon EE; Lewis RM; Allan J; Gamble GD; Phipps-Green AJ; Halperin Kuhns VL; Horne AM; Stamp LK; Merriman TR; Dalbeth N; Woodward OM
Nat Commun; 2020 Jun; 11(1):2767. PubMed ID: 32488095
[TBL] [Abstract][Full Text] [Related]
20. Structure-function relationships in ABCG2: insights from molecular dynamics simulations and molecular docking studies.
Ferreira RJ; Bonito CA; Cordeiro MNDS; Ferreira MU; Dos Santos DJVA
Sci Rep; 2017 Nov; 7(1):15534. PubMed ID: 29138424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
